Management of Bronchiolitis in Infants

Evidence Against Routine Use of Nebulized Budesonide

The American Academy of Pediatrics (AAP) explicitly recommends against the routine use of corticosteroids in the management of bronchiolitis 1
Randomized controlled trials have shown no difference in important clinical outcomes such as mean oxygen requirements and length of hospital stay 1, 2

Bronchiolitis is primarily a clinical diagnosis that does not require diagnostic testing 1
Management should focus on assessing hydration and ability to take fluids orally, providing supplemental oxygen if SpO2 falls persistently below 90%, and monitoring for signs of respiratory distress or failure 1
For infants at high risk, consider closer monitoring during the acute illness and Palivizumab prophylaxis according to guidelines 1

Using nebulized corticosteroids based on their effectiveness in asthma - bronchiolitis has a different pathophysiology 1
Continuing ineffective treatments - if a trial of any medication is attempted, objective measures should be used to document response 1, 2
Failing to implement appropriate infection control measures, which are crucial to prevent nosocomial spread of RSV 1

The American Academy of Pediatrics strongly recommends against administering albuterol to infants with bronchiolitis, as there is no evidence of benefit and potential for harm in this population, based on evidence showing no benefit in clinical outcomes 3
The American Academy of Pediatrics recommends against albuterol use in infants with RSV bronchiolitis, stating this as a strong recommendation based on high-quality evidence from multiple randomized controlled trials 3, 4, 5

Albuterol does not reduce length of hospital stay, duration of illness, or oxygen requirements in infants with RSV bronchiolitis, according to multiple randomized controlled trials 3, 4, 5
Albuterol use in infants with RSV bronchiolitis is associated with a lack of sustained benefit, with transient improvements in clinical scores disappearing within 30-60 minutes 4, 5

The American Academy of Pediatrics guideline for bronchiolitis management differs from asthma guidelines, which recommend albuterol for bronchospasm in older children, but this does not apply to infants with viral bronchiolitis due to different pathophysiology 3, 6

The Expert Panel Report 3 guidelines, as recommended by the American Academy of Allergy, Asthma, and Immunology, suggest ipratropium and albuterol for asthma exacerbations, but these recommendations do not apply to viral bronchiolitis in infants due to different underlying disease mechanisms 7, 8

For high-risk infants with severe RSV disease, the American Thoracic Society recommends considering nebulized ribavirin (20 mg/mL solution via small particle aerosol generator for 12-18 hours daily for 3-7 days), although it has not been shown to reduce length of hospital stay or need for oxygen/ventilation 9, 10

The American Academy of Pediatrics recommends against the use of albuterol and hypertonic saline for RSV bronchiolitis, but for patients with difficulty producing adequate sputum samples, hypertonic saline (2.7-3%) may be used for sputum induction only in diagnostic procedures, requiring ultrasonic nebulizer and monitoring for oxygen desaturation, as suggested by the Thorax journal 11
For immunocompromised patients with RSV lower respiratory tract disease, ribavirin (aerosolized or systemic) combined with IVIG may be considered, according to the Clinical Infectious Diseases journal 12
In mechanically ventilated infants with RSV, ribavirin via small particle aerosol generator (SPAG) should be used if antiviral therapy is indicated, as recommended by the Thorax journal 11

In infants with high‑risk conditions (e.g., prematurity, chronic lung disease, significant congenital heart disease, or immunodeficiency) or with severe RSV bronchiolitis, nebulized ribavirin may be considered at a concentration of 20 mg/mL delivered via a small‑particle aerosol generator for 12–18 hours per day over 3–7 days; however, clinical trials have not demonstrated a reduction in hospital length of stay or the need for supplemental oxygen or mechanical ventilation. 13

In the United Kingdom, ribavirin is generally not employed for the majority of children with RSV‑positive bronchiolitis. 13